Кафедра онкології
Permanent URI for this communityhttps://repo.knmu.edu.ua/handle/123456789/168
Browse
Browsing Кафедра онкології by Title
Now showing 1 - 20 of 156
- Results Per Page
- Sort Options
Item Chromosome aberrations in cancer patients with different tumour localizations undergone Co60 radiotherapy(2014) Maznyk, Nataliya; Tetyana, Sypko; Pshenichna, Nataliya; Krugova, Irina; Zabobonina, Larisa; Starenenkiy, ViktorItem Clinical oncology(2013) Starikov, Volodimir; Khodak, Andrei; Barannikov, KonstantinItem Complications at mammary gland cancer after salvage operation(2015) Khodak, Andrei; Khodak, VeraItem Determination of the lung cancer sensitivity to neoadjuvant chemotherapy(2014) Basylaishvili, StanislavItem Experience and prospects for the use of off-label drugs in oncology(2021-03-25) Старіков, Володимир Іванович; Дроговоз, Світлана Мефодіївна; Іванцик, Леся Богданівна; Щокіна, Катерина Геннадіївна; Drogovoz, S.; Starikov, V.; Ivantsyk, L.; Shchokina, K.Summary. According to the World Health Organization, half of all drugs available on the global pharmaceutical market are sometimes used for indications that are not included in the instruction for use. This method of therapy has the term “off-label use” which means the use “out of instruction”. Today, off-label drugs are also prescribed for cancer treatment. For example, a drug developed to treat one type of tumor can sometimes be used to treat other types of cancer. The treatment of certain types of pain with tricyclic antidepressants is also an example of the off-label drugs used in oncology. An example of an off-label prescription is anxiolytic medicine lorazepam, which can be used off-label as an antiemetic in cancer patients. Low doses of naltrexone are applied to treat cancer and autoimmune diseases. A retrospective analysis of modern oncotherapy indicates that oncologists often use off-label drugs in combination therapy, especially in the treatment of patients with concomitant diseases, in case of progressive development of the tumor, or to reduce the toxicity and cost of treatment components. American oncologists are of the opinion that if all the drugs prescribed by the International Recommendations failed in the treatment of cancer, doctors can prescribe off-label medications, but only if their effectiveness and safety are clearly established. The problem of the off-label use of drugs in oncology has not yet been studied in detail, however, this direction has certain promising prospects.Item Experimental study of receptor antagonist interleukin-1 cerebroprotective properties(2021-12) Старіков, Володимир Іванович; Щокіна, Катерина Геннадіївна; Дроговоз, Світлана Мефодіївна; Shchokina, K.; Drogovoz, S.; Kalko, K.; Starikov, V.In modern conditions craniocerebral trauma (ССT) is one of the most common pathologies. The search for new means of correcting ССT is an urgent task of medicine and pharmacy. According to the modern concept, the pathogenesis of brain lesions involves an increase in the production of proinflammatory cytokines, including interleukin-1. Attracts attention of the possibility to solve this problem by blockade of receptors of interleukin-1 (IL-1). The aim of this study was to evaluate the effectiveness of raleukin in traumatic CNS lesions in a model of traumatic brain injury in rats. Materials and methods. Raleukin injected at a dose of 15 mg / kg subcutaneously, referent-drug Piracetam (200 mg / kg) intraperitoneally 30 minutes before the modeling of CCT. Closed trauma of moderate severity was simulated under light etheric anesthesia (immediately after the lateral position of the animal) by the method of dosed impact on the parieto-occipital region with a weight of 0.0495 kg with an energy of 0.315 J in a special device. Immediately after the application of CCT determined the time of recovery of motor activity of animals. After 24 hours, the open field and rotating rod tests were repeated. This allowed us to assess the dynamics of the CNS. The main results. In the article are the results of studies of the effect of recombinant human receptor antagonist of interleukin-1 (Raleukin) status of animals after closed craniocerebral trauma. Found that Raleukin more effective of piracetam restores motor activity of animals in the acute period of experimental BI. Against the background of Raleukin recovery in the functional state of central nervous system (muscle tone and motor coordination, motor and research activity, emotional reaction) in craniocerebral trauma rehabilitation period is better than under the influence of piracetam.Item General oncology(2016) Starikov, Volodymyr; Khodak, AndreiThe manual sets out the general principles of diagnosis and treatment of malignant tumors This tutorial is for English-speaking students 5 courses. Textbook meets the requirements of the Bologna system of education in oncology and is designed for medical students III - IV accreditation levels.Item Morphological and immunohistochemical prognostic criteria for small cell lung cancers(2024) Yakovtsova, Iryna; Starikov, Volodymyr; Ivakhno, Ihor; Yanchevskyi, Oleksandr; Abdullaieva, Anhelina; Mirzebasov, MaksymItem Morphological evaluation of neoadjuvant chemotherapy in patients with lung cancer(2016) Basylaishvili, StanislavItem Oncolytic viruses as immunotherapeutic agents(Tehran University of Medical Sciences, 2020-09-25) Havrilov, Andrii; Trehub, YevheniiItem Organ-saving and reconstructive plastic surgery of breast cancer(2020) Tamm, T.; Vinnyk, Yu.; Starikov, V.; Prokopyuk, O.; Oleynik, G.; Vlasenko, V.Item Prognostic value of individual tumor cells in bone marrow, lymph nodes in patients with non-small cell lung carcinoma(2017) Starikov, Vladimir; Makarov, Vitalii; Syrovaya, Anna; Khodak, Andrei; Zavada, OksanaThe results of the examination of the bone marrow and distant lymph nodes for the presence of circulating tumor cells in 83 patients with non-small cell lung cancer T2-3N0M0, who had been radically operated, are given. Isolated tumor cells were determined by immune cytochemical and immune histochemical methods with the monoclonal antibodies to cytokeratins. Isolated tumor cells were detected in bone marrow in 30.1% and in lymph nodes in 20.5% of patients. The simultaneous presence of isolated tumor cells in bone marrow and lymph nodes was found in 18.1% of patients that significantly reduced the 3-year survival rate. Isolated tumor cells can be considered as a negative prognostic factor that must be taken into account when choosing the adjuvant treatment of lung carcinoma.Item The case of primary – plural malignant tumors of four localization(2016) Khodak, SergeyItem Thyroid cancer and background thyroid parenchyma patterns, a 29 years study(2014) Muzhichuk, Alexei; Bodjre, Kouame Eloi FrejusItem Triple-negative breast cancer: current treatment strategies and factors of negative prognosis(2022-02-02) Baranova, Anna; Krasnoselskyi, Mykola; Starikov, Volodymyr; Kartashov, Sergii; Zhulkevych, Igor; Vlasenko, Vadym; Oleshko, Kateryna; Bilodid, Olga; Sadchikova, Marina; Vinnyk, YuriiBreast cancer is the most common cancer in women and the most common cause of death in working-age women. According to the results of immunohistochemical studies, 10–20% of cases revealed a triple-negative type of breast cancer. This subtype is characterized by significant proliferative activity and growth rate, aggressive clinical course, and early metastasis. This leads to a suspicious prognosis and, accordingly, encourages an increase of surgical treatment radicalism and aggressive systemic treatment. This review briefly analyzes existing treatment strategies for triple-negative breast cancer with a focus on surgical treatment. Surgical treatment is an integral part of complex therapy. Currently, the attention of researchers is focused not only on the radicalism of the operation, ensuring long-term survival, but also on achieving a good cosmetic result that determines the quality of life of patients. In this aspect, organ-preserving and prosthetic methods of operations are promising, the feasibility and effectiveness of which are being discussed. The relevance of choosing the optimal method of operation is evidenced by the lack of generally accepted approaches based on informative markers for the prognosis of the course of the disease. Therefore, the choice of the optimal method of surgical treatment taking into account the individual characteristics of the patient and the tumor, indications for chemotherapy, and radiation therapy remains an unresolved issue and requires further research.Item Tumor stem cells as the source of malignant neoplasms risk(2015) Khodak, Andrei; Khodak, VeraItem Ultrastructure of non-small cell lung cancer cells(2015) Basylaishvili, Stanislav; Lukashova, OlgaItem Аrtificial intelligence in oncology, is it time to include its study in the course «Оncology and medical radiology»(2024) Baranova, Anna; Havrylov, Andrii; Kotenco, Olexander; Muzhychuk, Olexii; Sennikov, IhorItem Актуальні питання хірургії раку стравоходу і гастроезофагеального раку(2020) Красносельський, М.В.; Старіков, В.І.; Ходак, А.С.Item Анализ осложнений первичных реконструкций TRAM-лоскутом при раке молочной железы(2015) Красносельский, Николай Вилленович; Белый, Александр Николаевич